drugset / Trial / NCT01460134
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a study of CDX-1127, a therapy that targets the immune system and may act to promote anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias and lymphomas), as well as patients with select types of solid tumors.
Timeline
- Start
- 2011-10
- Primary completion
- 2015-12
- Completion
- 2017-10-16
Publications
- Background Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI, Taylor MH, Northfelt DW, Carson WE 3rd, Hawthorne TR, Davis TA, Yellin MJ, Keler T, Bullock T. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. J Clin Oncol. 2017 Jun 20;35(18):2028-2036. doi: 10.1200/JCO.2016.70.1508. Epub 2017 May 2.
- Ansell SM, Flinn I, Taylor MH, Sikic BI, Brody J, Nemunaitis J, Feldman A, Hawthorne TR, Rawls T, Keler T, Yellin MJ. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. Blood Adv. 2020 May 12;4(9):1917-1926. doi: 10.1182/bloodadvances.2019001079.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Varlilumab | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | Varlilumab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | Varlilumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Varlilumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Varlilumab | Monoclonal antibody | 10 mg/kg | Intravenous |